General Medicine and Primary Care

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Chris H. Cooper

Can new mask technology made with innovative materials better protect us from the coronavirus? Dr. Charles Turck speaks with Chris Cooper, Chief Science Officer and CEO of Airlock389, on improving mask technology after the supply shortage of masks during COVID-19.

Host: Matthew P. Bars, MS, CTTS, NCTTP

Guest: Michael C. Fiore, MD, MPH, MBA

Guest: Laura E. Crotty Alexander, MD

Dr. Matt Bars is joined by his two colleagues: Dr. Laura Crotty Alexander, Associate Professor of Pulmonary Critical Care Medicine at the University of California San Diego, and Dr. Michael Fiore, Professor of Medicine at the University of Wisconsin and Director of the University of Wisconsin Center for Tobacco Research Intervention. Together, they review tobacco dependence, the CHEST Tobacco Dependence Treatment Toolkit, and resources to help patients.

Supported in part by an independent medical educational grant from Pfizer.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Russell D. Cohen, MD, FACG, AGAF

Are patients with inflammatory bowel disease (IBD) at increased risk for COVID-19 infection? And what should we recommend for an IBD patient in remission who tests positive for COVID-19 versus a patient with active disease? These are just some of the questions that have arisen since the onset of the COVID-19 pandemic, and the questions Dr. Peter Buch explores with Dr. Russell Cohen, Director of Inflammatory Bowel Disease Center and Co-Director of the Advanced IBD Fellowship Program at the University of Chicago School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Ana C Zamora Martinez, MD

The COVID-19 pandemic led many clinicians to make life-altering decisions. Dr. Ana Zamora, a pulmonary disease and critical care specialist, discusses her work with Locum Tenens and why she decided it was time for a change.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Michael LaFauci

Guest: Jeffrey Wahl

Drug diversion is a safety concern that is often overlooked. What do we need to know about its impact, and what kind of devices can help? Dr. Charles Turck discusses drug diversion with Michael Lafauci and Jeffrey Wahl from Midas Healthcare Solutions.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Mark Pimentel, MD

Small intestinal bacterial overgrowth (SIBO) can be a challenging condition to navigate due to the several controversies surrounding its testing and treatment. Joining Dr. Peter Buch to discuss these complex issues and controversies is Dr. Mark Pimentel, Director of the Medically Associated Science and Technology Program at Cedars Sinai in Los Angeles and author of the “ACG Clinical Guideline Small Intestinal Bacterial Overgrowth” article published in the American Journal of Gastroenterology in 2020.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Prateek Sharma, MD

The evaluation and treatment of Barrett’s esophagus has been evolving over the last several years, but there are still many controversies and unanswered questions surrounding it. So to help answer some of these questions, Dr. Peter Buch speaks with Dr. Prateek Sharma, author of the “AGA Clinical Practice Update on Endoscopic Treatment of Barrett’s Esophagus with Dysplasia and/or Early Cancer Expert Review,” which was published in the Gastroenterology journal in 2020.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Asher A. Kornbluth, MD

Since the onset of the COVID-19 pandemic, many questions have arisen regarding the care of our patients with IBD. Are they at increased risk of COVID-19? How should we treat a patient with IBD who has active COVID-19? Should they get vaccinated, and if so, when? These are all questions Dr. Peter Buch addresses with Dr. Asher Kornbluth, Clinical Professor of Medicine and Gastroenterology at Mount Sinai School of Medicine in New York, to help us optimize our approach to care amid the COVID-19 pandemic.

Host: Neilanjan Nandi, MD

Guest: Jessica Allegretti, MD, MPH

Also known as C. diff for short, Clostridium difficile is an extremely difficult intestinal disease to manage…but not an impossible one. Joining Dr. Neil Nandi to share her insights on how to best mange C. diff in IBD patients is Dr. Jessica Allegretti, the Associate Director of the Crohn's and Colitis Center and the Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.

Host: Neilanjan Nandi, MD

Guest: Jessica Allegretti, MD, MPH

Bezlotoxumab is an IV antitoxin infusion treatment option for Clostridium difficile (C. diff) that’s been shown to reduce recurrence in IBD patients…so why isn’t it being used as much as it should be? Here to share the latest data and insights on bezlotoxumab as a treatment option for IBD patients with C. diff is Dr. Jessica Allegretti, Associate Director of the Crohn's and Colitis Center and Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.